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Abstract
Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-
related survival improves. There are few data on the natural history of bone disease in RCC.
Patients and methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for
398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.
Results: Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to
diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk.
Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second,
and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10
months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly
prolonged versus control (n= 186) (3 months vs 1 month for control; P,0.05).
Conclusions: RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced
this risk.
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Introduction
Kidney cancer is one of the 10 most frequently occurring
cancers in the Western world. More than 250,000 new cases of
kidney cancer are diagnosed annually and 116,000 patients die
from the disease [1]. Renal cell carcinoma (RCC) accounts for
80%–90% of kidney cancers. Almost one third of patients present
with metastatic disease and another 20% experience recurrence
and develop metastatic RCC after nephrectomy [2,3]. Despite
advances in systemic therapy and increases in survival over the
past decade, median survival in metastatic RCC remains low, at
19.7 months [4].
Bone metastasis has been identified as an independent
prognostic variable associated with poor survival in patients with
metastatic RCC [5]. With disease progression, approximately 30%
of RCC patients develop bone metastasis [6], representing the
second most common site of distant metastatic spread (after lung)
in advanced RCC. Bone metastases in RCC are mainly osteolytic
in nature, and decrease bone integrity, induce bone pain, and
result in significant morbidity for patients from the associated
skeletal-related events (SREs) [7], defined as pathologic fractures,
the need for radiotherapy for bone pain, surgical interventions to
treat or prevent an impending fracture, spinal cord and nerve root
compressions, and hypercalcemia. Skeletal-related events cause
significant decreased functional independence and loss of auton-
omy and impair patients’ quality of life [8]. Radiotherapy is the
most common SRE in RCC patients: approximately 81% of
patients with RCC receive radiotherapy, 42% develop long-bone
fracture, and 29% require orthopedic surgery [7]. Despite the fact
that bone metastasis from RCC causes higher rates of SREs
compared with many other tumors [9], metastatic bone disease in
renal cancer has received little attention to date. Previous studies
of the burden of bone disease in solid tumors included smaller
numbers of patients with RCC (ranging between 46 and 254)
[6,7,10–12], and the risk factors for SREs in these patients need
further elucidation. However, one study demonstrated a correla-
tion between elevated levels of an osteolysis marker, N-telopeptide
of type I collagen (NTX), and overall survival (P=0.0001) [12].
Nonetheless, there remains a paucity of data regarding the
demographics of bone metastasis and subsequent SREs in RCC
patients. Early detection and availability of novel primary
therapies are extending patient survival, thereby leaving patients
with bone metastasis at risk of SREs for longer durations. Thus,
understanding the natural history of bone metastases (and their
clinical management) for RCC in the ‘‘era’’ of targeted therapies is
of increasing importance for reducing healthcare costs and
improving patients’ quality of life. Here we report final data from
a large Italian multicenter study of patients with bone metastasis
from RCC.
Methods
Study Design
This was a retrospective, observational multicenter study of
medical records from 1986 to 2011 for patients diagnosed with
RCC who were treated at 23 different centers in Italy. Data were
collected from patients of all ages who received standard
treatments (i.e. not on clinical trials or experimental protocols) in
accordance with their treating physician’s practice. Only patients
with RCC who had at least one bone metastasis during the course
of their disease and who died of RCC or RCC-related
complications were included in the study. All patients were
deceased at the time of analysis. Patients were identified as having
bone metastasis if two of the following criteria were satisfied:
physician reported bone metastasis; bone metastasis identified on
bone scan; record of radiotherapy to bone as a palliative measure;
identification of bone metastasis by other imaging assessment (e.g.
standard x-rays, computed tomography scans, or magnetic
resonance imaging of the skeleton).
Data were collected throughout the disease course for all cancer
treatments, including surgery, radiation therapy, chemotherapy,
and targeted therapies. Variables assessed included age, sex,
histological subtype, number and sites of bone metastasis,
Memorial Sloan-Kettering Cancer Center (MSKCC) risk score,
time to appearance of bone metastasis, presence of bone pain,
times to first and subsequent SREs (from diagnosis of bone
metastasis), SRE types, survival after first SRE, and type and times
of bisphosphonate therapy. Patients, when possible, had docu-
mented bone pain scores on a visual analogue scale of 0–10.
This multicenter retrospective observational study has been
approved by the Ethics Committee of the coordinator center
(University Campus Bio-Medico of Rome). According to Ethics
Committee, a written consent was not needed. In fact, this is a
study considering only died patients whose recruitment in the
analysis did not influenced their treatment.
Statistical Analysis
Descriptive statistics were used for patient demographics and
incidence of SREs. All survival intervals were determined by the
Kaplan-Meier method. Differences in median time to first SRE
were evaluated by log-rank test. SPSS software (version 14.00;
SPSS, Chicago, IL) was used for statistical analysis. A P
value,0.05 was considered statistically significant.
Results
Patient Characteristics
After reviewing the records of more than 1800 patients who
died from RCC, 398 patients with bone metastasis were identified:
124 (31%) had bone metastasis at the time of RCC diagnosis and
269 (68%) developed bone metastasis after RCC diagnosis. Time
of development of bone metastasis relative to RCC diagnosis was
not determined for five patients. Of these 398 patients, 286 (72%)
were male (Table 1), consistent with the known male predom-
inance of RCC [1]. The median age was 63 years. Regarding
bisphosphonate use, 45% were treated with zoledronic acid
(ZOL), 8% received pamidronate, and 47% did not receive any
bisphosphonate treatment. Tumor histology was predominantly
clear cell (Table 1).
Skeletal Metastases
Most patients (281 [71%]) had multiple bone metastases and
116 (29%) had a single bone metastasis. The spinal column was
the most common site of bone metastasis (68% of patients).
Osteolytic lesions (79%) were far more prevalent in this group than
mixed (13%) or osteoblastic (7%) lesions (Table 1). The majority of
the patients (72%) experienced at least one SRE, 33% experienced
at least two SREs, and 12% experienced at least three SREs
(Figure 1). The incidences of different SREs (Figure 2) were
consistent with earlier reports [13], with radiotherapy to bone
being the most common SRE (62% of all events), followed by
surgery to bone, which accounted for 15% of the total number of
SREs experienced in this analysis.
Skeletal Outcomes and SREs
In patients without bone metastasis at primary diagnosis of
RCC (N=269), the median time to diagnosis of bone metastasis
was 25 months (range, 1–288 months). The median time to the
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appearance of bone metastasis in the overall population was 8
months (range, 0–288 months). The median level of maximum
bone pain experienced after diagnosis of bone metastasis was 7
(range, 0–10). The median pain level experienced at the time of
diagnosis of bone metastasis was 4 (range, 0–9).
The median number of SREs experienced by patients was one
(range, 0–6). The median time to first SRE after confirmed
diagnosis of bone metastasis was 2 months (range, 0–72 months),
indicative of the aggressiveness of bone metastasis in RCC. The
median time to second SRE was 5 months (range, 0–113 months),
and to third SRE was 12 months (range, 1–108 months). Median
survival from the diagnosis of bone metastasis was 12 months
(range, 1–178 months). Median survival after development of the
first SRE was 10 months (range, 0–144 months). More than 70%
of the patients experienced at least one SRE, and the median
survival in these patients was 14 months (range, 1–178 months).
Intriguingly, median survival in patients who did not experience
SREs (,30% of the study population) was only 9 months (range,
0–62 months). Although the precise reasons for this are not known,
it is likely that these patients had rapidly progressing visceral
metastases and correspondingly shorter survival.
Bone metastasis diagnosis also correlated with MSKCC risk:
median time to bone metastasis diagnosis in the good risk group
was 24 months (range, 0–288 months) versus 5 months (range, 0–
265 months) in the intermediate risk group and 0 months (range,
0–77 months) in the poor risk group (P,0.05; Figure 3). Time to
first SRE also correlated with MSKCC risk, albeit to a lesser
extent: median time to first SRE in the good risk group was 2
months (range, 0–72 months), which was similar to that in the
intermediate risk group (2 months [range, 0–26 months]) but
higher than that in the poor risk group (1 month [range, 0–25
months]) (Figure 4).
Bisphosphonate Therapy
Among the 398 patients with bone metastasis, 186 (47%) did not
receive any bisphosphonate treatment, 181 patients (45%) received
ZOL (administered at a dose of 4 mg every 4 weeks via 15-minute
infusion, with dose adjustments based on creatinine clearance),
and 31 patients (8%) received pamidronate (administered at a dose
of 90 mg every 4 weeks via 2-hour infusion). Zoledronic acid was
generally well tolerated; six patients (1.5%) developed osteonecro-
sis of the jaw (ONJ). Patients with ONJ underwent a computed
tomography scan for confirmation; no retrospective adjudication
was performed. It should be noted that no preventive dental care
was offered because many patients received treatment before
Table 1. Baseline Patient Demographics.
Characteristic Patients, n (%) (N=398)
Median age, y (range) 63 (16–92)
Sex
Male 286 (72)
Female 112 (28)
Tumor histotype
Clear cell 345 (87)
Papillary 22 (6)
Chromophobe 3 (,1)
Other 16 (4)
Not available 12 (3)
Number of bone metastases
1 116 (29)
$2 282 (71)
Location of lesion
Spinal column 271 (68)
Limb 155 (39)
Long bone 125 (31)
Other 68 (17)
Lesion type
Osteolytic 316 (79)
Osteoblastic 27 (7)
Mixed 52 (13)
Unknown 3 (,1)
doi:10.1371/journal.pone.0083026.t001
Figure 1. Skeletal-related events (SREs) are common in patients with bone metastasis from renal cell carcinoma (N=398).
doi:10.1371/journal.pone.0083026.g001
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2004. Patients receiving ZOL treatment had a longer median
survival time from diagnosis of bone metastasis compared with
patients not treated with bisphosphonates (15 months [range, 2–
120 months] versus 7 months [range, 1–178 months], respectively)
(P,0.05; Table 2). Patients who received ZOL also had a
significant delay in time to first SRE from diagnosis of bone
metastasis versus patients who did not receive bisphosphonate
treatment (3 months [range, 0–101 months] versus 1 month
[range, 0–22 months], P,0.05) (Figure 5).
Discussion
To our knowledge, this study is the largest multicenter survey to
investigate the natural history of metastatic bone disease in
patients with RCC. Bone metastasis was confirmed in approxi-
mately 22% of our screened RCC patients, which is lower than
previous estimates of bone metastasis in approximately 30% of
patients [6,7]. In the present study only patients with at least one
known bone metastasis were included, and several patients with
poorly documented bone metastasis were omitted. This might
explain the slightly lower incidence rate of bone metastasis in the
patient population of this study.
Among the 22% of RCC patients with bone metastasis,
approximately one third presented with bone metastasis at the
time of initial RCC diagnosis, whereas the remainder developed
bone metastasis during disease progression. This is in contrast with
a previous study by Woodward et al. [6], wherein an almost equal
distribution was reported between patients having bone metastasis
at the time of primary diagnosis and patients developing bone
metastasis at later times, which may be due to differences in
screening practices as well as the limits of bone metastasis
detection between studies. The axial skeleton was involved in 68%
of our RCC patients, which is lower than the 83% frequency
observed in breast cancer [14]. However, sites of metastatic
growth may be governed by the mechanism of metastasis. In
RCC, the majority of metastatic sites are found in the pelvis,
sacrum, and lumbar spine, although metastasis to the long bones is
not uncommon [15]. In fact, in one RCC study (N=31), 33% of
Figure 2. Incidence of skeletal-related events (SREs) in patients with bone metastases from renal cell carcinoma (N=398).
doi:10.1371/journal.pone.0083026.g002
Figure 3. Median time to bone metastases diagnosis according to MSKCC risk score. a Significant correlation between poor prognosis by
MSKCC risk score and median time to bone metastasis (P,0.05). MSKCC, Memorial Sloan-Kettering Cancer Center.
doi:10.1371/journal.pone.0083026.g003
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patients were found to have metastases in their femur or humerus
[16].
The median survival time of 12 months after diagnosis of
skeletal metastasis in our study population is consistent with
previously reported median survival times in patients with bone
metastasis from RCC. Median survival was paradoxically shorter
in patients with no SREs versus those with at least one SRE (9
months vs 14 months), possibly because of aggressive visceral
metastases affecting survival, or other complications they experi-
enced.
Bone metastasis has been identified as an independent
prognostic variable associated with poor survival in patients with
metastatic RCC [5]. In their skeletal history, the majority of these
patients may experience extremely debilitating skeletal complica-
tions (i.e. SREs) that profoundly impact their quality of life [8],
thereby highlighting the need for effective bone-targeted therapy.
Given the increasing incidence of RCC, improvements in overall
survival over the last decade [17], and the higher rates of
SRE occurrence in RCC patients compared with other cancer
patients [9], a better understanding of the natural history of
bone metastasis in RCC may provide insight into appropriate
monitoring for SREs.
Traditional cytokines or immunotherapy (interferon alfa or
interleukin-2) might have been used for some patients in our
retrospective analysis, but are not very effective in treating
metastatic bone disease [5]. In the past 6 years, widespread use
of targeted therapies directed at the vascular endothelial growth
factor (VEGF) and mammalian target of rapamycin (mTOR)
signaling pathways [18,19] has greatly changed the clinical
management of metastatic RCC. Since 2005, six molecular-
targeted agents have been approved in the United States and
Europe for treating patients with advanced or metastatic RCC:
sorafenib, sunitinib, bevacizumab (in combination with interferon
alfa), temsirolimus, everolimus, and pazopanib [19,20]. The
progression-free survival and overall survival times achieved with
these targeted agents are substantially superior to those of
cytokine-based therapies; however, there is no evidence for greater
efficacy of newer targeted therapies against bone disease in
particular (although recent data suggest that bisphosphonates may
augment the effects of sunitinib in this clinical setting) [17].
Bisphosphonates (such as ZOL, pamidronate, and clodronate) are
highly effective inhibitors of osteoclast-mediated bone resorption
and have been widely used for treating and preventing SREs from
bone metastases of breast cancer and prostate cancer, and from
bone lesions of multiple myeloma [21–24]. It is important to note
that although ZOL, pamidronate, and clodronate are all approved
for use in patients with bone metastasis from breast cancer or bone
lesions from multiple myeloma, ZOL is the only bisphosphonate
with approved efficacy in the RCC setting. More recently, the
receptor activator of nuclear factor kappa-B ligand inhibitor
denosumab has also shown broad efficacy for SRE reduction in
patients with bone metastasis from solid tumors [25]; however,
denosumab was not available outside of a clinical trial during the
period spanned by our retrospective database analysis.
A subanalysis of 74 RCC patient groups from a phase III,
placebo-controlled study showed that ZOL can significantly delay
the onset of SREs (P=0.006) and provide a numeric increase in
median overall survival in these patients [13]. Our larger study,
which included 181 patients treated with ZOL, showed similar
results, with a significant extension of time to first SRE and
increase in the median survival time after diagnosis of bone
Figure 4. Median time to first skeletal-related event (SRE) according to MSKCC risk score. MSKCC, Memorial Sloan-Kettering Cancer
Center.
doi:10.1371/journal.pone.0083026.g004
Table 2. Median Survival after Bone Metastases Diagnosis.
Variable Time, mo Range
All patients 12 1–178
By SRE history
Patients with at least one SRE 14 1–178
No SRE 9 0–62
After first SRE 10 0–144
By bisphosphonate treatment
No bisphosphonate 7 1–178
ZOL treated 15 2–120
SRE, skeletal-related event; ZOL, zoledronic acid.
doi:10.1371/journal.pone.0083026.t002
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metastasis. Taken together, these data support the beneficial
effects of ZOL in RCC patients. Additionally, although intrave-
nous bisphosphonates have been associated with dose- and
infusion rate-dependent decreases in renal function [26], in the
current study the renal safety profile of ZOL in RCC was similar
to the renal safety profile in patients not treated with bisphospho-
nates.
Limitations of this study include its retrospective design and
inclusion of an unselected heterogeneous cohort of patients with all
types of histologic variants of RCC, as well as a range of anticancer
therapies. However, the types of patients included in this study
represent the typical scenario of a real clinical practice. Another
limitation of a chart review is the heterogeneity of standardized
methods used for detecting bone metastases, with each method-
ology having its own limit of detection. Accurate and early
identification of patients with bone metastasis is crucial for
initiating treatment and delaying onset of SREs.
Early detection of bone metastasis is essential for optimal
management and treatment of SREs in patients with metastatic
RCC. With the advent of targeted therapies, it is likely that
patients will survive longer with an increased chance of developing
bone metastasis and SREs. To our knowledge, this retrospective
analysis is the largest multicenter study to demonstrate that bone
metastases from RCC are commonly aggressive and result in
relatively early onset of SREs in the majority of patients. This
retrospective analysis provides further support that ZOL is
effective for reducing the incidence of SREs in patients with bone
metastasis from RCC.
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